|
|
|
Market Research Report
Stem Cell Technology: Current Applications and Future Directions
| Published by |
BCC Research |
| Published |
July, 2008 |
Product code |
63236 |
| Content info |
208 pages |
| Price |
|
|
Stem Cell Technology: Current Applications and Future Directions published by BCC Research in July, 2008. This report consists of 208 pages and the price starts from US $ 4850.
Abstract
This report:
- Analyzes adult and embryonic stem cell technology, applications (current
and future), as well as the impact of stem cell focused products and services
on healthcare markets and beyond.
- Provides quantitative market forecasts for near term applications and
documents trends that impact product demand. Segments markets by both
technology and application.
- Covers the latest stem cell research and commercialization advances with
implications for end users such as the healthcare market as well as the
biotechnology, and pharmaceutical markets.
- Includes impact of stem cells in biotech for products such as stem cell
derived protein products, diagnostic related stem cell technology, and stem
cell banking. Additionally, the current and future impact of stem cell
technology in the research and development of pharmaceuticals through the use
of disease specific stem cell lines and cancer stem cells is included.
- Provides complete company profiles, competitive analysis, industry
structure, market shares, and patent analyses
INTRODUCTION
Study goals and objectives
BCC' s goal in conducting this study was to determine the current status of
stem cell technology and its applications and assess its growth potential over
a 5-year period from 2007 to 2012. We are particularly interested in the
position of adult stem cell technology and applications as compared to the
development and applications of embryonic stem cells. Additionally, we are
interested in the market potential of emerging breakthroughs in stem cell
research such as induced pluripotent stem cells (iPS).
Our key objective is to present a comprehensive analysis of the current state
of stem cell research and development (R&D) as well as the current stem cell
market and its future direction.
Reasons for doing the study
Stem cell technology has been described as the next revolution in medicine.
Therapeutic stem cell applications have been proposed to address a wide range
of health care needs. We are interested in determining the current state of
stem cell technology, where stem cells are currently being applied, and
evaluating the potential growth for stem-cell-based applications. In
particular, we are interested in discerning the current technological state
and potential growth of adult stem-cell-based applications as compared to
embryonic-stem-cell-based applications. Additionally, we are interested in
looking forward to emerging advancements in stem cell technology and
evaluating the potential impact these advancements could have on the
development of stem-cell-based products.
Scope of report
This report encompasses the two major classes of stem cells: adult and
embryonic. BCC examined the current state of stem cell technology, focusing on
these two major classes as well as emerging breakthroughs in stem cell
research and development. Further, BCC evaluated the current stem cell market
in the United States (U.S.) and examined the future impact of stem-cell-based
technology, presenting forecasts of growth over the next 5 years.
Technological issues covering current and emerging stem-cell-based therapeutic
applications are also reviewed. Further issues considering stem-cell-based
therapeutic research and development and its applications are additionally
discussed.
Given the major role that the U.S. plays in the world health care market (both
as provider and consumer), this analysis is focused predominantly on the
current state of stem cell technology and its applications in the U.S., with
some discussion regarding worldwide stem cell technology impact. In addition
to technological considerations as well as market issues, we examine
governmental (legal and political) as well as social issues regarding the
research and development of stem-cell-based therapeutic applications. The
present and projected status of stem-cell-based technology is compared for
high value applications of cellular therapeutics, engineered tissue for
transplantation, and therapeutic stem cell banking. Further, the present and
projected status of stem-cell-based therapeutic research applications are
projected for high value applications such as cell-based assays, diagnostic
tools, and necessary support reagents and materials.
Intended audience
Given the broad application potential of stem-cell-based technology, the
present study will be of interest to the life science industry, in particular,
to individuals in the biotechnology, pharmaceutical, and medical device
markets. Further, it will be of interest to manufacturers of reagents and
tools that support the research and development of stem-cell-based products
and services.
Further, this report will of be of interest to professionals presently focused
in areas of stem cell research, development, and commercialization as well as
those surveying potential stem-cell-based opportunities for investment.
Additionally, this report will be of particular interest to health care
professionals surveying the potential therapeutic application of
stem-cell-based technology and its growth.
Information Sources
BCC surveyed approximately 60 companies directly and actively engaged in stem
cell focused research and product development to obtain data for this study.
Contained within this study are companies pursuing both adult stem-cell-based
products as well as embryonic-based stem cell applications. Of particular
focus are companies centered on the development of cellular therapeutics,
engineered tissue for transplantations, and therapeutic banking of stem cells
for future medical applications. Also surveyed were academic stem cell
researchers as well as life science industry professionals. Additionally,
extensive data was compiled from primary scientific source literature and
current financial and trade information as well as government and regulatory
sources, both federal and state.
Table of Contents
- Stem Cell Technology: Current Applications and Future Directions
Chapter- 1: SUMMARY
- SUMMARY TABLE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE,
THROUGH 2012 ($ MILLIONS)
- SUMMARY FIGURE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE
REVENUE, 2005-2012 ($ MILLIONS)
Chapter- 2: OVERVIEW
- HISTORICAL REVIEW OF STEM CELL BIOLOGY
- HISTORY OF STEM CELL BIOLOGY
- EARLY OBSERVATION AND CLASSIFICATIONS
- STEM CELL CLASSIFICATION
- Derivation of Human Tissue Types during Development from Embryonic Stem
Cells
- TABLE 1 DERIVATION OF HUMAN TISSUE TYPES DURING DEVELOPMENT
- FIGURE 1 FLOW DIAGRAM OF HUMAN DEVELOPMENT PROCESS
- Derivation of Human Tissue Following Maturation from Adult Stem Cells
- STEM CELL CONCEPTS IN HEALTH CARE
- INITIAL STEM CELL ISOLATION AND CHARACTERIZATION
- Initial Stem Cell Isolation ...(Continued)
- EARLY CELL-BASED THERAPEUTICS
- Xeno Transplants
- Blood Transfusions and Bone Marrow Transplantation
- AREAS OF HEALTH CARE NEED AND STEM CELLS
- DISEASE- AND DEGENERATION-RELATED HEALTH CARE NEED
- Disease- and Degeneration-...(Continued)
- ORGAN TRANSPLANTATION-RELATED HEALTH CARE NEED
- CANCER- AND GENETIC DISORDER-RELATED HEALTH CARE NEED
- INFECTIOUS DISEASE-RELATED HEALTH CARE NEED
- HEALTH CARE NEED AND COSTS
- Health Care Need and Costs (Continued)
- CURRENT STATE OF REGENERATIVE MEDICINE
- STEM CELL CLASSIFICATION BASED ON SOURCE
- Embryonic Stem Cells
- Adult (and Progenitor) Stem Cells
- Adult (and Progenitor) ...(Continued)
- STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL
- Pluripotent Stem Cell Differentiation Potential
- Multipotent Stem Cell Differentiation Potential
- Unipotent Stem Cell Differentiation Potential
- TABLE 2 STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL
- DYNAMICALLY EVOLVING AREAS IN STEM CELL BIOLOGY
- CLONAL STEM CELLS LINES IN NONHUMAN PRIMATES
- EMBRYONIC STEM CELL LINES DERIVED FROM INNER CELL MASS OF VIABLE EMBRYOS
- STEM CELLS FROM NEONATAL FLUID
- ADULT STEM SOURCING/NICHES
- Adult Stem Sourcing/Niches (Continued)
- TABLE 3 ADULT STEM CELL TYPES AND POTENTIAL TISSUE SOURCES
- DISEASE-SPECIFIC EMBRYONIC STEM CELL LINES
- ADULT STEM CELL REPROGRAMMING
- PERSONALIZED HEALTH CARE
- CELL-BASED THERAPEUTICS
- Using Embryonic-derived Stem Cells
- Using Adult/Progenitor-derived Stem Cells
- ENGINEERED TISSUE FOR TRANSPLANTATION
- Using Embryonic-derived Stem Cells
- Using Adult Stem Cells (and Progenitor Cells)
- THERAPEUTIC STEM CELL BANKING
- STEM-CELL-BASED BIOMEDICAL RESEARCH
- MARKETS FOR STEM-CELL-BASED CELLULAR THERAPEUTICS
- HEALTH CARE NEED AND THE APPLICATION OF STEM CELLS
- Cardiovascular System-related Clinical Stem Cell Applications
- Nervous System-related Clinical Stem Cell Applications
- Skeletal/Muscular System-related Clinical Stem Cell Applications
- Whole Organ (Tissue) System-related Clinical Stem Cell Applications
- Stem-cell-related Cancer and Clinical Applications
- Infectious Disease/Cancer (General) and Clinical Applications
- GOVERNMENT REGULATIONS AND THE USE OF STEM CELLS IN RESEARCH AND
THERAPEUTIC APPLICATIONS
- GOVERNMENT REGULATION OF THE APPLICATION OF STEM-CELL-BASED THERAPEUTICS
- Government Regulation of...(Continued)
- GOVERNMENT REGULATION OF THE APPLICATION OF STEM-CELL-BASED RESEARCH
- TABLE 4 THE NATIONAL INSTITUTES OF HEALTH STEM CELL RESEARCH FUNDING,
2004-2009 ($ MILLIONS)
- TABLE 4 (CONTINUED)
- FIGURE 2 THE NATIONAL INSTITUTES OF HEALTH HUMAN STEM CELL RESEARCH
FUNDING, 2004-2009 ($ MILLIONS)
- TABLE 5 THE NATIONAL INSTITUTES OF HEALTH HUMAN EMBRYONIC STEM CELL
REGISTRY
- TABLE 5 (CONTINUED)
- TABLE 6 STATES FUNDING STEM-CELL-RELATED RESEARCH
- FUTURE IMPACT OF STEM CELLS ON UNMET HEALTH CARE NEED
- FUTURE IMPACT OF STEM ...(CONTINUED)
- STEM CELL TECHNOLOGY IN THE REGENERATIVE MEDICINE MARKET
- TABLE 7 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE
MEDICINE, THROUGH 2012 ($ MILLIONS)
- FIGURE 3 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE
MEDICINE, 2005-2012 ($ MILLIONS)
- INTRODUCTION TO STEM CELLS TECHNOLOGY IN REGENERATIVE MEDICINE MARKET
- STEM CELLS IN CELLULAR THERAPEUTICS
- Stem Cells in Cellular Therapeutics (Continued)
- Stem Cells in Cellular Therapeutics (Continued)
- FIGURE 4 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN CELLULAR
THERAPEUTICS
- Stem Cells in Cellular Therapeutics (Continued)
- TABLE 8 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED
THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, THROUGH 2012 ($
MILLIONS)
- FIGURE 5 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED
THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, 2005-2012 ($ MILLIONS)
- Stem Cells in Cellular Therapeutics towards Engineering Tissue in Vitro
for Transplantation
- Stem Cells in Cellular Therapeutics ...(Continued)
- Stem Cells in Cellular Therapeutics ...(Continued)
- FIGURE 6 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN ENGINEERING TISSUE
FOR TRANSPLANTATION
- THERAPEUTIC STEM CELL BANKING
- FIGURE 7 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC BANKING OF STEM CELLS
- Therapeutic Stem Cell Banking (Continued)
- TABLE 9 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING,
THROUGH 2012 ($ MILLIONS)
- FIGURE 8 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING,
2005-2012 ($ MILLIONS)
- INTRODUCTION TO STEM CELLS TECHNOLOGY IN THERAPEUTIC-RELATED RESEARCH
- STEM CELL TECHNOLOGY IN CELL-BASED ASSAYS AND DIAGNOSTIC RESEARCH
APPLICATIONS
- TABLE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED THERAPEUTIC
RESEARCH ($ MILLIONS)
- FIGURE 9 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED THERAPEUTIC
RESEARCH, 2005-2012 ($ MILLIONS)
- THERAPEUTIC STEM-CELL-RELATED RESEARCH SUPPORT
- TABLE 11 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED CELL-BASED
ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, THROUGH 2012 ($ MILLIONS)
- FIGURE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED CELL-BASED
ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, 2005-2012 ($ MILLIONS)
- FACTORS DRIVING AND INHIBITING APPLICATION OF STEM CELL TECHNOLOGY
- Factors Driving and Inhibiting ...(Continued)
- Factors Driving and Inhibiting ...(Continued)
- Factors Driving and Inhibiting ...(Continued)
- TABLE 12 FACTORS DRIVING AND INHIBITING THE APPLICATION OF
STEM-CELL-BASED THERAPEUTICS
Chapter- 3: MARKETS BY TYPES OF APPLICATIONS
- INTRODUCTION TO STEM-CELL-THERAPEUTIC-BASED APPLICATIONS
- STEM CELL APPLICATIONS: REGENERATIVE MEDICINE
- Stem Cell Applications Specifically by Tissue Type
- Stem Cell Applications Specifically by Organ System Type
- Stem Cell Applications in Infectious Disease, Genetic Disorders, and
Cancer-related
- TABLE 13 STEM CELL TECHNOLOGY APPLICATIONS IN REGENERATIVE MEDICINE
- STEM CELL APPLICATIONS IN RESEARCH AND DEVELOPMENT
- Stem Cell Applications in Academic Research
- Stem Cell Applications in Biotechnology and Medical Device Research
- Stem Cells in Pharmaceutical Research
- TABLE 14 STEM CELL TECHNOLOGY AREAS OF APPLICATION WITHIN THE LIFE
SCIENCES
Chapter- 4: STEM CELL TECHNOLOGY AND DEVELOPMENT
- STEM CELL PRODUCTION
- STEM CELL ACQUISITION
- CHARACTERIZATION AND EXPANSION
- MAINTENANCE AND STORAGE
- FIGURE 11 FLOW DIAGRAM FOR PROCESS OF STEM CELL PRODUCTION
- STEM CELL PRODUCTION ECONOMICS
- STEM CELL PRODUCTION ECONOMICS (CONTINUED)
- NOVEL STEM CELL PRODUCTION DEVELOPMENTS
- ISOLATION AND ENGINEERING
- NOVEL DEVELOPMENTS IN THE PRODUCTION OF ADULT STEM CELLS
- NOVEL DEVELOPMENTS IN THE PRODUCTION OF EMBRYONIC STEM CELLS
- Novel Developments in the Production ...(Continued)
- LEADERS IN STEM CELL RESEARCH DEVELOPMENT
- ACADEMIC RESEARCH AND DEVELOPMENT LEADERS
- Academic Stem Cell Research and Development Scientists
- George Q. Daley, MD, Ph.D.
- Kevin Eggan, Ph.D.
- Doug Melton, Ph.D.
- Amy Wagers, Ph.D.
- Robert Langer, Sc.D.
- Irving Weissman, MD
- Stuart Orkin, MD
- Joseph Vacanti, MD
- Kenneth Chien, MD, Ph.D.
- Rudolf Jaenisch, MD
- Daniel Tenen, MD
- Konrad Hochedlinger, Ph.D.
- Paul Matsudaira, Ph.D.
- Anthony Atala, MD
- Elaine Fuchs, Ph.D.
- David J. Mooney, Ph.D.
- James A. Thomson, Ph.D.
- Shinya Yamanaka, MD, Ph.D.
- Kacey G. Marra, Ph.D.
- Gordon Keller, Ph.D.
- Johnny Huard, Ph.D.
- Hans Keirstead, Ph.D.
- Shoukhrat Mitalipov, Ph.D.
- Gordon Keller, Ph.D.
- TABLE 15 HIGHLIGHTED STEM CELL RESEARCH PUBLICATIONS, 2005-2008
- TABLE 15 (CONTINUED)
- TABLE 15 (CONTINUED)
- INDUSTRY RESEARCH AND DEVELOPMENT LEADERS
- TECHNOLOGY PATENT ANALYSIS
- GENERAL TRENDS
- TABLE 16 STEM CELL PATENT TRENDS, 2000-2008
- FIGURE 12 STEM CELL PATENT TRENDS, 2000-2008
- TRENDS BY COUNTRY
- TABLE 17 STEM CELL PATENT COUNTRY CODES, 2000-2008
- TABLE 18 STEM CELL PATENT TRENDS BY COUNTRY, 2000-2008
- TABLE 19 STEM CELL PATENT TRENDS BY COUNTRY OF PATENTS, 2000-2008 (%)
- FIGURE 13 STEM CELL PATENT TRENDS BY COUNTRY % OF PATENTS, 2000-2008 (%)
- TRENDS BY COMPANIES
- TABLE 20 STEM CELL PATENT TRENDS BY COMPANIES ASSIGNED TWO OR MORE
PATENTS, 2000-2008
Chapter- 5: STEM CELL INDUSTRY STRUCTURE
- DRIVING FORCES IN STEM-CELL-BASED INDUSTRIES
- DRIVING FORCES IN THE HEALTH CARE MARKET
- BIOTECHNOLOGY
- PHARMACEUTICAL
- COMPETITIVE ADVANTAGES IN STEM-CELL-BASED INDUSTRIES
- TECHNOLOGY DEVELOPMENT AND UTILIZATION
- COST OF NEW PRODUCT DEVELOPMENT, MANUFACTURING, AND LAUNCH
- Cost of New Product Development, ... (Continued)
- MARKET POSITIONING AND CAPTURE
- Market Positioning and Capture (Continued)
- Market Positioning and Capture (Continued)
- IMPORTANT SHIFTS IN INDUSTRY
- CONTINUOUSLY EVOLVING TECHNOLOGICAL BASE
- Continuously Evolving Technological Base (Continued)
- EFFECTS OF FLUCTUATIONS IN FEDERAL GOVERNMENT AND FOOD AND DRUG
ADMINISTRATION REGULATORY FACTORS
- TABLE 21 RESTRICTIONS ON STEM CELL RESEARCH BY STATE
- TABLE 21 (CONTINUED)
- TABLE 21 (CONTINUED)
- TABLE 21 (CONTINUED)
- TABLE 21 (CONTINUED)
- TABLE 21 (CONTINUED)
- TABLE 21 (CONTINUED)
- Food and Drug Administration Approval Requirements for Implementation of
Stem-cell-based Therapeutics
- STAGE OF STEM CELL LIFE CYCLE
- TABLE 22 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008
- FIGURE 14 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008
- TABLE 23 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY,
2000-2008
- FIGURE 15 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY,
2000-2008
- TABLE 24 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL
BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)
- FIGURE 16 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL
BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)
- IMPACT ON EXISTING HEALTH CARE MARKET MAY BE SIGNIFICANT
- MAJOR STEM CELL COMPANIES
- MAJOR STEM CELL MARKETS
- Stem Cell Market Segmentation
- Stem Cell Market Forces
- Stem Cell Market Forces (Continued)
- GENERAL STEM CELL TECHNOLOGY ISSUES
- STEM CELL TECHNOLOGY ISSUES BY TECHNOLOGY TYPE
- Embryonic Stem Cells
- Adult Stem Cells
- STEM CELL COMPANIES PERCENT MARKET SHARE
- Stem Cell Companies Percent Market Share (Continued)
- TABLE 25 MARKET SHARE OF STEM CELL THERAPEUTICS (AND BANKING) COMPANIES,
2005-2007 (%)
Chapter- 6: COMPANY PROFILES
- AASTROM BIOSCIENCES, INC.
- TABLE 26 AASTROM BIOSCIENCES, INC. STEM CELL CLINICAL TRIALS
- TABLE 26 (CONTINUED)
- TABLE 27 AASTROM BIOSCIENCES, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- ALDAGEN, INC
- TABLE 28 ALDAGEN, INC. STEM CELL CLINICAL TRIALS
- TABLE 29 ALDAGEN, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- ADVANCED CELL TECHNOLOGY, INC.
- TABLE 30 ADVANCED CELL TECHNOLOGY, INC. STEM CELL CLINICAL TRIALS
- TABLE 31 ADVANCED CELL TECHNOLOGY, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- TABLE 31 (CONTINUED)
- ARTERIOCYTE, INC.
- TABLE 32 ARTERIOCYTE, INC. STEM CELL CLINICAL TRIALS
- ATHERSYS, INC.
- BD BIOSCIENCES
- BIO-MATRIX SCIENTIFIC GROUP, INC.
- BIOE
- TABLE 33 BIOE STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- BIOHEART, INC.
- TABLE 34 BIOHEART, INC. STEM CELL CLINICAL TRIALS
- TABLE 35 BIOHEART, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- CELGENE CORP.
- CELLERANT THERAPEUTICS, INC.
- TABLE 36 CELLERANT THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
- TABLE 37 CELLERANT THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- CELLULAR DYNAMICS INTERNATIONAL, INC.
- COGNATE BIOSERVICES, INC.
- TABLE 38 COGNATE BIOSERVICES, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- CRYO-CELL INTERNATIONAL, INC.
- CYTOMATRIX, LLC
- TABLE 39 CYTOMATRIX, LLC STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- CYTORI THERAPEUTICS, INC.
- TABLE 40 CYTORI THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
- TABLE 41 CYTORI THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- TABLE 41 (CONTINUED)
- ENDGENITOR TECHNOLOGIES, INC.
- FORTICELL BIOSCIENCE, INC.
- TABLE 42 FORTICELL BIOSCIENCE, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- GERON CORP
- TABLE 43 GERON CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- HEALTHEUNIVERSE, INC.
- TABLE 44 HEALTHEUNIVERSE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- INTERNATIONAL STEM CELL CORPORATION
- INVITROGEN CORPORATION
- MATTEK CORPORATION
- TABLE 45 MATTEK CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- MEDISTEM LABORATORIES, INC.
- TABLE 46 MEDISTEM LABORATORIES, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- MEDRA, INC.
- MILLIPORE
- MORPHOGENESIS, INC.
- TABLE 47 MORPHOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- MG BIOTHERAPEUTICS, LLC
- MORAGA BIOTECHNOLOGY CORPORATION
- NEOSTEM, INC.
- TABLE 48 NEOSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- NEURALSTEM, INC.
- TABLE 49 NEURALSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- NEUROGENERATION
- NEURONYX, INC.
- TABLE 50 NEURONYX, INC. STEM CELL CLINICAL TRIALS
- TABLE 51 NEURONYX, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- NUTECH MEDICAL, INC.
- NOVOCELL, INC.
- TABLE 52 NOVOCELL, INC STEM CELL CLINICAL TRIALS
- TABLE 53 NOVOCELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- OPEXA THERAPEUTICS, INC.
- TABLE 54 OPEXA THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
- ORGANOGENESIS, INC.
- TABLE 55 ORGANOGENESIS, INC. STEM CELL CLINICAL TRIALS
- TABLE 56 ORGANOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- OSIRIS THERAPEUTICS, INC.
- TABLE 57 OSIRIS THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
- TABLE 57 (CONTINUED)
- TABLE 58 OSIRIS THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- PHARMASTEM THERAPEUTICS, INC.
- TABLE 59 PHARMASTEM THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- PRIMEGEN BIOTECH, LLC
- PROGENITOR CELL THERAPY, LLC
- REGENETECH, INC
- TABLE 60 REGENETECH, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- SANERON CCEL THERAPEUTICS, INC.
- STEM CELL INNOVATIONS
- TABLE 61 STEM CELL INNOVATIONS STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- STEM CELLS, INC.
- TABLE 62 STEM CELLS, INC. STEM CELL CLINICAL TRIALS
- TABLE 63 STEM CELLS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY
LICENSED
- STEM CELL THERAPY INTERNATIONAL CORP.
- STEMCELL PHARMA, INC.
- STEMCYTE, INC.
- STEMEDICA CELL TECHNOLOGIES, INC.
- TENGION, INC.
- TABLE 64 TENGION, INC. STEM CELL CLINICAL TRIALS
- THERADIGM, INC.
- TABLE 65 THERADIGM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- THERMOGENESIS CORP.
- VESTA THERAPEUTICS, INC.
- TABLE 66 VESTA THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- VIACELL, INC.
- TABLE 67 VIACELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
- VIACORD
- VISTAGEN THERAPEUTICS, INC.
- TABLE 68 VISTAGEN THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
- TABLE 69 VISTAGEN THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR
EXCLUSIVELY LICENSED
- VITRO DIAGNOSTICS, INC.
- VITRO DIAGNOSTICS, INC. (CONTINUED)
Chapter- 7: INTERNATIONAL ASPECTS OF REGENERATIVE MEDICINE/STEM CELL MARKET
- INTERNATIONAL ASPECTS OF...
- TABLE 70 LEADING GLOBAL REGENERATIVE MEDICINE/STEM CELL COMPANIES
Chapter- 8: REFERENCES
- REFERENCES
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
- REFERENCES (CONTINUED)
Chapter- 9: APPENDIX A ABBREVIATIONS
- APPENDIX A - ABBREVIATIONS
Chapter- 10: APPENDIX B GLOSSARY
- APPENDIX B - GLOSSARY
- APPENDIX B - GLOSSARY (CONTINUED)
- APPENDIX B - GLOSSARY (CONTINUED)
Chapter- 11: APPENDIX C STEM CELL PATENTS, 2000-2008
- TABLE 71 STEM CELL PATENTS BETWEEN THE YEARS 2000 AND 2008
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
- TABLE 71 (CONTINUED)
Stem Cell Technology: Current Applications and Future Directions
August 1st, 2008
US MARKET FOR STEM CELL TECHNOLOGIES SLATED FOR HIGH GROWTH THROUGH 2012
Wellesley, Mass-According to a new technical market research report, STEM CELL TECHNOLOGY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS from BCC Research, the domestic market for stem cell technology is expected to increase from $112.0 million in 2007 to $423.1 million in 2012, a compound annual growth rate (CAGR) of 30.5%
The market is divided into cellular therapeutics and therapeutic banking categories. Stem cells in therapeutic banking have the larger share of the market, worth $65.9 million in 2007 and expected to increase to $155.7 million in 2012, for a CAGR of 18.8%.
Cellular therapeutics should be the faster growing segment. Cellular therapeutics generated $46.1 million in 2007 and is expected to generate $267.4 million in 2012, a CAGR of 42.1%.
The advent of stem cell technology has reignited the regenerative medicine market with hopes of powerful new therapeutics geared towards addressing unmet healthcare needs such as cardiovascular disease, neurological diseases, metabolic diseases, organ failure, a wide range of injuries, and even age related degeneration.
Although stem cell based therapeutics hold great promise, the delivery of actual readily available treatments is still projected to be at least five if not 10 or more years away. People looking to capitalize on the potential future therapeutic applications of stem cells have been preserving their stem cells, and stem cell banking has become a slow but growing market.
Stem cell research and development will continue to play a significant role in the present and future commercialization of stem cell based products and services and may develop into a substantial parallel market to stem cell based therapeutics as these tools mature, and potentially move into adjacent life science markets such as pharmaceutical testing and drug discovery.
|
 |
